Trials / Completed
CompletedNCT00742261
A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors
An Open-label, Randomized, Two-way Balanced Crossover Study to Investigate the Bioavailability of Two Forms ofGSK1363089 in Subjects With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study to compare 2 different chemical forms of GSK1363089.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK1363089 | Two-part study to evlauate the relative bioavailability of GSK1363089 from a free base formulation (GSK1363089G) compared with the biophosphate salt formulation (GSK1363089A) (Part 1) and to assess the safety of the GSK1363089 biophosphate formulation when administered three times a week until disease progression (Part 2). |
Timeline
- Start date
- 2008-08-11
- Primary completion
- 2009-06-24
- Completion
- 2009-06-24
- First posted
- 2008-08-27
- Last updated
- 2017-07-07
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00742261. Inclusion in this directory is not an endorsement.